Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

751
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
751
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

696
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
696
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

523
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
523
Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.01:25

Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.

4.0K
Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
4.0K
COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

2.0K
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
2.0K
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

491
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
491

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Vascular compliance phenotyping in pulmonary arterial hypertension (a PVDOMICS study).

JHLT open·2026
Same author

Qualitative Interviews of Physicians Managing Patients With Methamphetamine-Associated Pulmonary Arterial Hypertension: Understanding the Unmet Medical Needs From a Provider Lens.

Pulmonary circulation·2026
Same author

Updates to mortality on Mount Everest: 1921-2024.

The Journal of physiology·2026
Same author

One size doesn't fit all?

Annals of the American Thoracic Society·2026
Same author

Pulmonary vascular response to high-intensity interval training in deployment-related respiratory disease: a pilot clinical trial.

Annals of the American Thoracic Society·2026
Same author

AltitudeOmics: Breathing variability at rest and during exercise across 16 days of acclimatization to hypobaric hypoxia.

The Journal of physiology·2025

Related Experiment Video

Updated: Mar 9, 2026

Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat
08:34

Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat

Published on: November 18, 2018

7.8K

Long-Term Health Outcomes in High-Altitude Pulmonary Hypertension.

Jeffrey C Robinson1, Cheryl Abbott1, Christina A Meadows1

  • 11 Colorado Pulmonary Vascular Disease Center, Division of Pulmonary Sciences and Critical Care Medicine, Department of Medicine, University of Colorado School of Medicine , Aurora, Colorado.

High Altitude Medicine & Biology
|January 7, 2017
PubMed
Summary

High-altitude pulmonary hypertension (HAPH) in adolescents did not lead to significant pulmonary hypertension (PH) later in life. However, individuals with past HAPH experienced more functional limitations, underscoring the need for further research.

Keywords:
high-altitude population healthhigh-altitude pulmonary hypertensionhypoxic pulmonary hypertension

More Related Videos

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
08:08

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Published on: May 11, 2015

14.7K
The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats
07:29

The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats

Published on: March 8, 2019

11.4K

Related Experiment Videos

Last Updated: Mar 9, 2026

Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat
08:34

Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat

Published on: November 18, 2018

7.8K
Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
08:08

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Published on: May 11, 2015

14.7K
The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats
07:29

The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats

Published on: March 8, 2019

11.4K

Area of Science:

  • Cardiology
  • Pulmonology
  • Environmental Health

Background:

  • High-altitude pulmonary hypertension (HAPH) is a known comorbidity in high-altitude populations.
  • Limited research exists on the long-term health consequences of HAPH.
  • Adolescent HAPH may predispose individuals to pulmonary hypertension (PH) later in life.

Purpose of the Study:

  • To determine if adolescent HAPH predisposes to later-life PH.
  • To identify correlations between altitude exposure, HAPH, functional class, and comorbidities.

Main Methods:

  • A cohort of 28 adolescents from Leadville, Colorado, who underwent right heart catheterization in 1962 was re-evaluated.
  • Participants were located, and living subjects completed health surveys assessing PH, comorbidities, and functional status.
  • Original study data included resting mean pulmonary arterial pressure (mPAP ≥25 mmHg) for PH diagnosis.

Main Results:

  • 75% of the original study participants were located for follow-up.
  • Individuals with prior HAPH showed a higher likelihood of exertional limitation (WHO functional class >1).
  • No significant differences in PH prevalence or medical comorbidities were found between those with and without adolescent HAPH 55 years later.

Conclusions:

  • While significant PH was not reported in surveyed individuals, past HAPH was linked to increased functional limitations.
  • Further investigation into the long-term health impacts of HAPH is crucial given the global high-altitude population.
  • Altitude exposure and HAPH require continued study regarding their chronic health effects.